Mark A. Socinski, MD

Articles by Mark A. Socinski, MD

Do Oncogenic Drivers Exist in Squamous Cell Carcinoma of the Lung?

ByLiza C. Villaruz, MD,Timothy F. Burns, MD, PhD,Mark A. Socinski, MD

September 16th 2013

The Cancer Genome Atlas provides us with our first thorough insight into the genetic heterogeneity of squamous cell carcinoma of the lung; whether these findings will translate into personalized squamous cell lung cancer therapy is yet to be determined.

Commentary (Stinchcombe et al): Perspectives on Salvage Therapy for Non–Small-Cell Lung Cancer

ByThomas E. Stinchcombe, MD,D. Neil Hayes, MD, MPH,Mark A. Socinski, MD

July 1st 2005

We applaud Dr. Cappuzzo andcolleagues for an excellentreview of an emerging fieldin lung cancer treatment. Since 2000,three drugs (docetaxel [Taxotere],pemetrexed [Alimta], and erlotinib[Tarceva]) have been approved by theUS Food and Drug Administration(FDA) for second-line therapy in non–small-cell lung cancer (NSCLC) basedon the results of phase III trials (seeTable 1).[1-4] It is also possible thatsimilar approval will be sought for otherdrugs (eg, topotecan [Hycamtin]),[5]and gefitinib (Iressa) remains an optionfor treatment in the third-line setting.